Results 131 to 140 of about 97,443 (231)

Caesarean Scar Ectopic Pregnancy in Early Gestation: A Scoping Review of Definitions and Diagnostic Approach

open access: yesBJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 5, Page 888-899, April 2026.
ABSTRACT Background Caesarean scar ectopic pregnancy (CSEP) is defined by the implantation and development of a gestational sac inside a caesarean scar defect, but variations in classification systems and diagnostic criteria exist. Objectives This study aimed to systematically review the different criteria used in the medical literature to diagnose ...
Simrit Nijjar   +5 more
wiley   +1 more source

Something Old, Something New, Something Borrowed… About the Placenta. [PDF]

open access: yesEpigenomes
Milova N   +4 more
europepmc   +1 more source

Risk Factors and Outcomes Associated With Delayed Villous Maturation in Placenta: A Systematic Review and Meta‐Analysis

open access: yesBJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 5, Page 900-921, April 2026.
ABSTRACT Background Delayed villous maturation (DVM) is a placental maturation disorder that mainly affects maternal‐to‐foetal oxygen transfer. Objectives We conducted a systematic review, meta‐analysis, and sensitivity analysis exploring study heterogeneities (I2) of risk factors and outcomes associated with histopathological findings of DVM.
Muhammad Pradhiki Mahindra   +6 more
wiley   +1 more source

Kisspeptin Restores Placental mTOR Signaling and Improves Glucose Homeostasis Mediators Disrupted by Maternal Hypothyroidism in Rats

open access: yesActa Physiologica, Volume 242, Issue 4, April 2026.
ABSTRACT Aim Reduced placental mTOR signaling is associated with intrauterine growth restriction and impaired maternal and placental metabolism. Since maternal hypothyroidism induces intrauterine growth restriction, and maternal treatment with kisspeptin‐10 (Kp10) has been shown to improve feto‐placental development in hypothyroid rats, this study ...
Bianca Reis Santos   +9 more
wiley   +1 more source

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

open access: yesInternational Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke   +30 more
wiley   +1 more source

Modeling human placental biology: a review of organoid technologies. [PDF]

open access: yesFront Cell Dev Biol
Bashi A, Joseph T, Schuch V, Johnson EL.
europepmc   +1 more source

Home - About - Disclaimer - Privacy